| Nov 9 |
ProQR Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
| Nov 8 |
ProQR Therapeutics sees cash runway into mid-2027
|
| Nov 7 |
ProQR Announces Third Quarter 2024 Operating and Financial Results
|
| Oct 17 |
Why TSMC Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
|
| Sep 30 |
ProQR Therapeutics files for $300M mixed securities shelf
|
| Sep 10 |
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference
|
| Aug 10 |
ProQR Therapeutics Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
| Jun 23 |
Institutions own 25% of ProQR Therapeutics N.V. (NASDAQ:PRQR) shares but retail investors control 46% of the company
|
| Jun 18 |
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
|
